5-Ethoxy-2-[2-(morpholin-4-ium-4-yl)ethylsulfanyl]-1H-benzimidazol-3-ium dichloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-Ethoxy-2-[2-(morpholin-4-ium-4-yl)ethylsulfanyl]-1H-benzimidazol-3-ium dichloride
• 英文别名: 4-[2-[(6-ethoxy-1H-benzimidazol-3-ium-2-yl)sulfanyl]ethyl]morpholin-4-ium;dichloride
• 化学式: C15H23Cl2N3O2S
• 分子量: 380.3
• InChiKey: OFMVMQZFMVQDFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.23
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Polymorphic forms of 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride and processes for their preparation
  申请人：AFOFARM, CJSC

  公开号：EP2423200A1

  公开（公告）日：2012-02-29

  Polymorphic forms of 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride commonly known as Afobazole and processes for their preparation.

  5-乙氧基-2-[2-(吗啉基)-乙硫基]苯并咪唑二盐酸盐（俗称阿福巴唑）的多晶型及其制备工艺。
• ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110245231A1

  公开（公告）日：2011-10-06

  The invention relates to novel drug substance for the treatment of alcohol dependence, pharmaceutical composition, medicament and method for treatment of dependence on using ethyl alcohol containing beverages. The invention provides a drug substance for treating alcohol dependence in human and warm-blooded animals representing substituted 1H-benzimidazoles of the general formula 1 or pharmaceutically acceptable salts and/or hydrates thereof wherein: W represents S or S═0 group; R 1 represents one or more substituent selected from hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, optionally substituted azaheterocyclyl; R 2 represents hydrogen or optionally substituted C 1 -C 4 alkyl; R 3 and R 4 independently represent optionally identical substituents selected from hydrogen or optionally substituted C 1 -C 4 alkyl; R 5 represents an alkyl substituent selected from hydrogen, optionally substituted C 1 -C 7 alkyl, optionally substituted aryl, optionally substituted heterocyclyl, C 1 -C 4 alkoxycarbonyl, optionally substituted aminocarbonyl.
• [EN] METHODS AND USES OF BEMITHYL AND DERIVATIVES FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS<br/>[FR] PROCÉDÉS ET UTILISATIONS DE BÉMITHYLE ET DE DÉRIVÉS POUR LE TRAITEMENT D'UNE MALADIE PULMONAIRE, D'UNE STÉATOSE HÉPATIQUE ET DE TROUBLES RÉNAUX
  申请人：ALGERNON PHARMACEUTICALS INC

  公开号：WO2020191501A1

  公开（公告）日：2020-10-01

  Methods and uses of bemithyl and derivatives of the formula (I) for treating fibrotic diseases are taught, and in particular, chronic lung disease, including idiopathic pulmonary fibrosis; non-alcoholic fatty liver disease, and in particular, non-alcoholic fatty liver, and non-alcoholic steatohepatitis; and kidney disorders, and in particular, renal fibrosis and/or chronic kidney disease.